Yatai pharm(SZ:002370) Mei Ri Jing Ji Xin Wen·2025-09-30 06:21Core Viewpoint - The announcement of a potential change in control at Asia-Pacific Pharmaceutical has attracted market attention, particularly given the company's history of six consecutive years of net profit losses excluding non-recurring items [1][2]. Group 1: Financial Performance - Asia-Pacific Pharmaceutical has reported net profit losses excluding non-recurring items for six consecutive years from 2019 to 2024, with losses of -1.94 billion, -143 million, -239 million, -117 million, -68.94 million, and -28.13 million respectively [1]. - Although the company has shown a reduction in losses from 2022 to 2024, it has not yet returned to profitability [1]. Group 2: Regulatory Issues - The company has faced multiple regulatory challenges, including receiving inquiry letters from the Shenzhen Stock Exchange regarding its financial performance and cash flow from 2019 to 2022 [2]. - In April 2021, the Zhejiang Securities Regulatory Bureau issued an administrative penalty against the company for false financial reporting from 2016 to 2018, resulting in a five-year market ban for the then-chairman and general manager [2]. - The company has also received warnings and public reprimands from the Shenzhen Stock Exchange during the 2020 to 2022 period [2]. Group 3: Control Change Significance - The planned change in control is seen as a critical opportunity for the company to seek new development avenues and improve its operational status [2]. - A new controlling shareholder may bring in a new management team and strategic planning, potentially enhancing corporate governance, operational efficiency, and market expansion [2]. - However, uncertainties remain regarding whether the new controlling shareholder can effectively address existing operational issues and enhance the company's competitive edge in a challenging market [2][3].